200% Trump tariff shock? India’s cheap pills may still beat US rivals
The Economic Times has reported a new India-focused foreign affairs development: “200% Trump tariff shock? India’s cheap pills may still beat US rivals.” The publisher's feed describes the story as follows: US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).
Intellectual Janata displays only original summaries of externally sourced news and links readers to the original publisher.


